Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective

被引：0

作者：

M. Charokopou

P. McEwan

S. Lister

L. Callan

K. Bergenheim

K. Tolley

R. Postema

R. Townsend

M. Roudaut

机构：

[1] Pharmerit International,Centre for Health Economics

[2] Swansea University,undefined

[3] HEOR,undefined

[4] Bristol-Myers Squibb Pharmaceuticals Ltd,undefined

[5] AstraZeneca UK Ltd,undefined

[6] AstraZeneca,undefined

[7] Tolley Health Economics Ltd.,undefined

[8] Bristol-Myers Squibb,undefined

[9] AstraZeneca,undefined

来源：

BMC Health Services Research | / 15卷

关键词：

SGLT 2; DPP-4i; Type 2 diabetes mellitus; Cost-effectiveness analysis;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 9 条

[1]

Hex N(2012)Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs Diabet Med 29 855-862

[2]

Bartlett C(2011)Globalization of Diabetes: the role of diet, lifestyle, and genes Diabetes care 34 1249-1257

[3]

Wright D(2010)A population model evaluating the costs and benefits associated with different oral treatment strategies in people with type 2 diabetes Diabetes Obes Metab 12 623-630

[4]

Taylor M(2007)Computer modeling of diabetes and its complications Diabetes care 30 1638-46

[5]

Varley D(undefined)undefined undefined undefined undefined-undefined

[6]

Hu FB(undefined)undefined undefined undefined undefined-undefined

[7]

McEwan P(undefined)undefined undefined undefined undefined-undefined

[8]

Evans M(undefined)undefined undefined undefined undefined-undefined

[9]

Bergenheim K(undefined)undefined undefined undefined undefined-undefined

← 1 →